Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/77096
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAdrie Bekkeren_US
dc.contributor.authorEric H. Decloedten_US
dc.contributor.authorGretchen Sladeen_US
dc.contributor.authorMark F. Cottonen_US
dc.contributor.authorHelena Rabieen_US
dc.contributor.authorTim R. Cresseyen_US
dc.date.accessioned2022-10-16T07:22:45Z-
dc.date.available2022-10-16T07:22:45Z-
dc.date.issued2021-06-01en_US
dc.identifier.issn15376591en_US
dc.identifier.issn10584838en_US
dc.identifier.other2-s2.0-85107390423en_US
dc.identifier.other10.1093/cid/ciaa1026en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85107390423&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/77096-
dc.description.abstractAbacavir is a potential option for prophylaxis and early treatment of human immunodeficiency virus (HIV), but no data are available in neonates. Ten neonates administered a single abacavir dose of 8 mg/kg before 15 days of life had substantially higher exposures than those reported in infants and children, with no reported adverse events.en_US
dc.subjectMedicineen_US
dc.titleSingle Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV)en_US
dc.typeJournalen_US
article.title.sourcetitleClinical Infectious Diseasesen_US
article.volume72en_US
article.stream.affiliationsHarvard T.H. Chan School of Public Healthen_US
article.stream.affiliationsUniversity of Liverpoolen_US
article.stream.affiliationsStellenbosch Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.